查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球智能药丸市场：按应用（胶囊内窥镜、药物输送、患者监护）、目标区域（食道、小肠、大肠、胃）、最终用户（医院、诊断中心）和地区进行预测（到2028年）
市场调查报告书
商品编码
1298021

全球智能药丸市场：按应用（胶囊内窥镜、药物输送、患者监护）、目标区域（食道、小肠、大肠、胃）、最终用户（医院、诊断中心）和地区进行预测（到2028年）

Smart Pills Market by Application (Capsule Endoscopy, Drug Delivery, Patient Monitoring), Target Area (Esophagus, Small Intestine, Large Intestine, Stomach), End User (Hospitals, Diagnostic Centers), Region - Global Forecast to 2028
出版日期: | 出版商: MarketsandMarkets | 英文 150 Pages | 订单完成后即时交付

价格
简介目录

全球智能药丸市场规模预计在预测期内将以 11.8% 的复合年增长率增长，从 2023 年的 6 亿美元增至 2028 年的 11 亿美元。

该市场的主要增长动力包括对非侵入性诊断监测设备的需求不断增长以及胶囊内窥镜技术的重大进步。 此外，对先进药物输送系统的需求不断增长以及对快速药物开发流程的需求预计将为进入者提供市场机会。 另一方面，智能药丸在某些条件下的技术限制预计将在一定程度上抑制未来市场的增长。

“生命体征监测领域在预测期内将以最高复合年增长率增长”

从应用来看，生命体征监测领域预计在预测期内将以最高复合年增长率增长。 这是由于对精确体温测量的需求不断增长，以及传统生命体征监测设备与数字健康系统的集成度较差。 随着医疗保健系统努力实现互操作性和全面的患者记录，对与数字医疗保健系统顺利集成的生命体征监测设备的需求不断增长。 由于智能药丸具有先进的连接性以及与数字医疗系统的兼容性，对简化集成的需求不断增长，预计将增加智能药丸的采用。

“在预测期内，结直肠应用将占据第二大市场份额”

按目标区域划分，结肠应用将在 2022 年占据第二大份额。 促成因素包括结直肠癌发病率的增加以及对炎症性肠病和其他胃肠道疾病进行有效筛查、诊断和监测的需要。 未来结直肠癌的增加将有助于结肠智能药丸的广泛采用，因为智能药丸可以到达传统方法难以观察到的结肠区域。

“2022年诊断中心细分市场将占据第二大市场份额”

按最终用户计算，诊断中心是智能药丸市场的第二大最终用户。 其原因包括技术进步、对非侵入性诊断的需求以及诊断准确性的提高。 智能药丸在诊断中心的集成已成为推动采用的关键因素，因为它提供了扩展的诊断功能、改善的患者体验、提高的运营效率和促进远程诊断的能力。

“欧洲将在 2022 年占据第二大市场份额”

到 2022 年，按地区划分，欧洲将占据第二大份额。 这是由于人口老龄化以及越来越多地使用胶囊内窥镜来治疗消化道出血等因素。 欧洲胃肠内窥镜协会 (ESGE) 指南提出的胶囊内窥镜检查建议为卫生专业人员提供了标准化方法，并提高了为患者提供的护理质量。 因此，胶囊内窥镜检查消化道出血的使用有所增加，推动了对智能药丸和相关技术的需求。

内容

第一章简介

第 2 章研究方法

第 3 章执行摘要

第 4 章重要考虑因素

第五章市场概述

  • 简介
  • 市场动态
    • 驱动程序
    • 制约因素
    • 机会
    • 任务
  • 行业趋势
  • 技术分析
  • 波特五力分析
  • 生态系统分析
  • 价值链分析
  • 专利分析
  • 价格分析
  • 重大会议和活动
  • 监管机构、政府机构和其他组织
  • 监管分析
  • 主要利益相关者和采购标准

第 6 章：智能药丸市场：按目标区域

  • 简介
  • 小肠
  • 大肠
  • 食道
  • 胃

第 7 章：智能药丸市场：按应用划分

  • 简介
  • 胶囊内窥镜检查
  • 生命体征监测
  • 靶向药物输送

第 8 章：智能药丸市场：按最终用户划分

  • 简介
  • 医院
  • 诊断中心
  • 其他最终用户

第 9 章：智能药丸市场：按地区

  • 简介
  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 亚太地区其他地区
  • 其他地区（ROW）

第 10 章竞争格局

  • 概述
  • 主要公司采取的策略
  • 主要企业的企业评价象限
  • 企业足迹分析
  • 竞争场景

第 11 章公司简介

  • 主要公司
    • OLYMPUS CORPORATION
    • CAPSOVISION, INC.
    • MEDTRONIC PLC
    • INTROMEDIC
    • ANX ROBOTICA CORP.
    • SHENZHEN JIFU MEDICAL TECHNOLOGY CO., LTD.
    • CHONGQING JINSHAN SCIENCE & TECHNOLOGY (GROUP) CO., LTD.
    • RF CO., LTD.
    • ETECTRX
    • BODYCAP
    • OTSUKA AMERICA PHARMACEUTICAL, INC.
    • CHECK-CAP LTD.

第12章附录

简介目录
Product Code: MD 3264

The global smart pills market is projected to reach USD 1.1 billion by 2028 from USD 0.6 billion in 2023, at a CAGR of 11.8% during the forecast period. Growth in this market is majorly driven by the rise in demand for non-invasive diagnostic monitoring devices, technological advancements in capsule endoscopy and significant advancements in capsule endoscopy technology. The growing demand for advanced drug delivery systems and need for a rapid drug development process are expected to offer opportunities for market players during the forecast period. On the other hand, technological incompetence of smart pills in some conditions is expected to restrain the market growth to some extent in the coming years

"The vital sign monitoring segment is projected to grow at the highest CAGR during the forecast period."

Based on application, the market for smart pills is divided into segments for target drug devliery, capsule endoscopy, and vital sign monitoring. The vital sign monitoring segments is projected to grow at the highest CAGR during the forecast period. This is due to the increasing need for precise and accurate measurement of inner body temperature and insufficient integration with digital health systems in conventional vital sign monitoring devices. As healthcare systems strive for interoperability and comprehensive patient records, the rising need for vital sign monitoring devices that integrate smoothly with digital health systems becomes crucial. The growing demand for streamlined integration is expected to increase the adoption of smart pills due to advanced connectivity and compatibility with digital health systems.

"The large intestine target area accounted for the second largest share of the market during the forecast period. "

Based on target area, the smart pills market is broadly segmented into, small intestine, large intestine, esophagus, and stomach. The large intestine target area accounted for the second largest share in 2022 and this is attributed to the increasing cases of colorectal cancer and need for effective screening, diagnosis, and monitoring of inflammatory bowel diseases and other gastrointestinal disorders. The increasing cases of colorectal cancer have contributed to the growing adoption of smart pills in large intestine as smart pills can reach areas of the colon that may be challenging to visualize with traditional methods.

The diagnostic centers segment accounted for the second largest share of the market in 2022

Based on end users, the smart pills market is broadly segmented into diagnostic centers, hospitals, and other end users. Diagnostic centers are the second largest end users of the smart pills market. This can be attributed to the advancements in technology, demand for non-invasive diagnostics, and improved diagnostic accuracy. The integration of smart pills in diagnostic centers has been a key factor in driving utilization by offering expanded diagnostic capabilities, enhanced patient experience, improved operational efficiency, and the ability to facilitate remote diagnostics.

Europe accounted for the second largest share of the smart pills market in 2022

In 2022, Europe accounted for the second largest share of the smart pills market. This can be attributed to factors such as growth in ageing population and increased utilization of capsule endoscopy for gastrointestinal bleeding. The endorsement of capsule endoscopy by the European Society of Gastrointestinal Endoscopy (ESGE) guidelines provides a standardized approach for healthcare professionals, enhancing the quality of care provided to patients. As a result, there is a growing demand for smart pills and related technologies, driven by the increased utilization of capsule endoscopy for gastrointestinal bleeding.

The break up of the profile of primary participants in the smart pills market:

  • By Company Type: Tier 1- 60%, Tier 2- 30%, and Tier 3-10%
  • By Designation: C-level Executives- 50%, Directors- 40% , and Others- 10%.
  • By Region: North America- 45%, Europe- 35%, Asia Pacific- 15%, and Rest of the World- 5%.

Key players in the Smart pills market

The key players operating in the smart pills market include RF Co., Ltd (Japan), etectrx(US), Olympus Corporation (Japan), BodyCap (France), Chongqing Jinshan Science Technology (Group) Co., Ltd (China), Check-Cap Ltd. (Israel), CapsoVision,Inc. (US), ANX Robotica Corp. (US), Medtronic plc (US), IntroMedic (South Korea), Shenzen Jifu Medical Technology Co., Ltd (China) and Otsuka America Pharmaceutical, Inc. (US).

Research Coverage:

The report analyzes the smart pills market and aims at estimating the market size and future growth potential of this market based on various segments such as application, target area, and end user. The report also includes a product portfolio matrix of various smart pills products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, service offerings, and key market strategies.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:

  • Market Penetration: Comprehensive information on product portfolios offered by the top players in the global smart pills market. The report analyzes this market by applications, target area and end user.
  • Service Enhancement/Innovation: Detailed insights on upcoming trends in the global smart pills market
  • Market Development: Comprehensive information on the lucrative emerging markets by applications, target area and end user.
  • Market Diversification: Exhaustive information about new services or service enhancements, growing geographies, recent developments, and investments in the global smart pills market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global smart pills market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • FIGURE 1 SMART PILLS MARKET: MARKET SEGMENTATION
    • 1.3.2 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES
  • 1.8 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • FIGURE 2 RESEARCH DESIGN
    • 2.1.1 SECONDARY RESEARCH
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
    • FIGURE 3 PRIMARY SOURCES
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Insights from primary experts
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    • 2.1.3 MARKET SIZE ESTIMATION
    • FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
    • FIGURE 6 SMART PILLS MARKET: SEGMENTAL EXTRAPOLATION
    • FIGURE 7 SMART PILLS MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2023-2028)
    • FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • 2.2 MARKET BREAKDOWN AND DATA TRIANGULATION METHODOLOGY
    • FIGURE 9 SMART PILLS MARKET: DATA TRIANGULATION METHODOLOGY
  • 2.3 MARKET SHARE ANALYSIS
  • 2.4 STUDY ASSUMPTIONS
  • 2.5 LIMITATIONS
    • 2.5.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.6 RISK ASSESSMENT
    • TABLE 1 SMART PILLS MARKET: RISK ASSESSMENT ANALYSIS
  • 2.7 RECESSION IMPACT ANALYSIS

3 EXECUTIVE SUMMARY

    • FIGURE 10 SMART PILLS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 11 SMART PILLS MARKET, BY TARGET AREA, 2023 VS. 2028 (USD MILLION)
    • FIGURE 12 SMART PILLS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    • FIGURE 13 GEOGRAPHICAL SNAPSHOT OF SMART PILLS MARKET

4 PREMIUM INSIGHTS

  • 4.1 SMART PILLS MARKET OVERVIEW
    • FIGURE 14 RISING TECHNOLOGICAL ADVANCEMENTS IN CAPSULE ENDOSCOPES TO DRIVE MARKET
  • 4.2 NORTH AMERICA: SMART PILLS MARKET, BY END USER AND COUNTRY
    • FIGURE 15 HOSPITALS ACCOUNTED FOR LARGEST MARKET SHARE IN US FOR 2022
  • 4.3 SMART PILLS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 16 CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
  • 4.4 SMART PILLS MARKET: REGIONAL MIX
    • FIGURE 17 NORTH AMERICA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • 4.5 SMART PILLS MARKET: DEVELOPING VS. EMERGING MARKETS
    • FIGURE 18 EMERGING MARKETS TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 19 SMART PILLS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • TABLE 2 SMART PILLS MARKET: IMPACT ANALYSIS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising demand for noninvasive diagnostic monitoring devices
      • 5.2.1.2 Technological advancements in capsule endoscopy
      • 5.2.1.3 Increasing incidence of colon cancer
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High costs
      • 5.2.2.2 Technical limitations associated with accuracy of smart pills
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growing demand for advanced drug delivery systems
      • 5.2.3.2 Rising need for rapid drug delivery development
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Patient privacy concerns
  • 5.3 INDUSTRY TRENDS
    • 5.3.1 ADVANCEMENTS IN SENSOR TECHNOLOGY
    • 5.3.2 INTEGRATION WITH WEARABLE DEVICES
  • 5.4 TECHNOLOGY ANALYSIS
    • 5.4.1 SELF-POWERED INGESTIBLE SMART PILL
    • 5.4.2 ADAPTIVE FRAME RATE TECHNOLOGY
    • 5.4.3 IMAG (INGESTIBLE MICRODEVICES FOR ANATOMIC MAPPING OF GASTROINTESTINAL TRACT)
    • TABLE 3 SENSOR AND BATTERY TYPES USED FOR CAPSULE ENDOSCOPY PRODUCTS
    • TABLE 4 SENSOR USED FOR VITAL SIGN MONITORING AND DRUG INGESTION TRACKING PRODUCTS
    • TABLE 5 SMART PILLS MARKET: DRUGS UNDER PIPELINE
  • 5.5 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 6 PORTER'S FIVE FORCES ANALYSIS
    • 5.5.1 THREAT OF NEW ENTRANTS
    • 5.5.2 THREAT OF SUBSTITUTES
    • 5.5.3 BARGAINING POWER OF SUPPLIERS
    • 5.5.4 BARGAINING POWER OF BUYERS
    • 5.5.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.6 ECOSYSTEM ANALYSIS
    • FIGURE 20 SMART PILLS MARKET: ECOSYSTEM ANALYSIS
  • 5.7 VALUE CHAIN ANALYSIS
    • FIGURE 21 SMART PILLS MARKET: VALUE CHAIN ANALYSIS
  • 5.8 PATENT ANALYSIS
    • 5.8.1 PATENT PUBLICATION TRENDS FOR SMART PILLS
    • FIGURE 22 PATENT PUBLICATION TRENDS (JANUARY 2012-DECEMBER 2022)
    • 5.8.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
    • FIGURE 23 TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR SMART PILLS PATENTS (JANUARY 2012-DECEMBER 2022)
    • FIGURE 24 TOP APPLICANTS FOR SMART PILLS PATENTS (COUNTRY/REGION) (JANUARY 2012-JANUARY 2022)
    • TABLE 7 SMART PILLS MARKET: LIST OF PATENTS (2020-2023)
  • 5.9 PRICING ANALYSIS
    • TABLE 8 PRICE RANGE FOR SMART PILLS (2022)
  • 5.10 KEY CONFERENCES AND EVENTS
    • TABLE 9 SMART PILLS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS (2023-2024)
  • 5.11 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 10 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.12 REGULATORY ANALYSIS
    • 5.12.1 NORTH AMERICA
      • 5.12.1.1 US
    • TABLE 11 US FDA: MEDICAL DEVICE CLASSIFICATION
    • TABLE 12 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
    • 5.12.2 EUROPE
    • 5.12.3 ASIA PACIFIC
      • 5.12.3.1 Japan
    • TABLE 13 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
      • 5.12.3.2 China
    • TABLE 14 CHINA: CLASSIFICATION OF MEDICAL DEVICES
  • 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY APPLICATION
    • TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY APPLICATION (%)
    • 5.13.2 BUYING CRITERIA
    • FIGURE 26 KEY BUYING CRITERIA FOR SMART PILLS, BY APPLICATION
    • TABLE 16 KEY BUYING CRITERIA FOR SMART PILLS, BY APPLICATION

6 SMART PILLS MARKET, BY TARGET AREA

  • 6.1 INTRODUCTION
    • TABLE 17 SMART PILLS MARKET, BY TARGET AREA, 2021-2028 (USD MILLION)
  • 6.2 SMALL INTESTINE
    • 6.2.1 RISING INCIDENCE OF SMALL INTESTINE DISORDERS TO DRIVE MARKET
    • TABLE 18 SMART PILLS MARKET FOR SMALL INTESTINE, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.3 LARGE INTESTINE
    • 6.3.1 INCREASING INCIDENCE OF COLORECTAL CANCER TO SUPPORT MARKET GROWTH
    • TABLE 19 SMART PILLS MARKET FOR LARGE INTESTINE, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.4 ESOPHAGUS
    • 6.4.1 EVALUATION AND MONITORING OF BARRETT'S ESOPHAGUS TO PROPEL MARKET
    • TABLE 20 SMART PILLS MARKET FOR ESOPHAGUS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.5 STOMACH
    • 6.5.1 IMPROVED DIAGNOSTIC ACCURACY TO SUPPORT MARKET GROWTH
    • TABLE 21 SMART PILLS MARKET FOR STOMACH, BY COUNTRY, 2021-2028 (USD MILLION)

7 SMART PILLS MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
    • TABLE 22 SMART PILLS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • 7.2 CAPSULE ENDOSCOPY
    • 7.2.1 ABILITY TO ASSESS GASTROINTESTINAL BLEEDING AND SMALL-BOWL TUMORS TO DRIVE MARKET
    • TABLE 23 CAPSULE ENDOSCOPES OFFERED BY KEY MARKET PLAYERS
    • TABLE 24 SMART PILLS MARKET FOR CAPSULE ENDOSCOPY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.3 VITAL SIGN MONITORING
    • 7.3.1 LAUNCH OF INNOVATIVE SENSOR TECHNOLOGIES TO PROPEL MARKET
    • TABLE 25 VITAL SIGN MONITORING SMART PILLS UNDER PIPELINE
    • TABLE 26 SMART PILLS MARKET FOR VITAL SIGN MONITORING, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.4 TARGETED DRUG DELIVERY
    • 7.4.1 SITE-SPECIFIC DRUG DELIVERY INTEGRATION WITH SMART PILLS TO SUPPORT MARKET GROWTH
    • TABLE 27 TARGETED DRUG DELIVERY SMART PILLS UNDER PIPELINE
    • TABLE 28 SMART PILLS MARKET FOR TARGETED DRUG DELIVERY, BY COUNTRY, 2021-2028 (USD MILLION)

8 SMART PILLS MARKET, BY END USER

  • 8.1 INTRODUCTION
    • TABLE 29 SMART PILLS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 8.2 HOSPITALS
    • 8.2.1 RISING NEED FOR TECHNOLOGICALLY ADVANCED ENDOSCOPY PROCEDURES TO DRIVE MARKET
    • TABLE 30 SMART PILLS MARKET FOR HOSPITALS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.3 DIAGNOSTIC CENTERS
    • 8.3.1 GROWING PREFERENCE FOR NONINVASIVE DIAGNOSTICS TO PROPEL MARKET
    • TABLE 31 SMART PILLS MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.4 OTHER END USERS
    • TABLE 32 SMART PILLS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)

9 SMART PILLS MARKET, BY REGION

  • 9.1 INTRODUCTION
    • TABLE 33 SMART PILLS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 34 CAPSULE ENDOSCOPY MARKET, BY REGION, 2021-2028 (MILLION UNITS)
    • TABLE 35 VITAL SIGN MONITORING MARKET, BY REGION, 2021-2028 (MILLION UNITS)
  • 9.2 NORTH AMERICA
    • FIGURE 27 NORTH AMERICA: SMART PILLS MARKET SNAPSHOT
    • TABLE 36 NORTH AMERICA: SMART PILLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 37 NORTH AMERICA: SMART PILLS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 38 NORTH AMERICA: SMART PILLS MARKET, BY TARGET AREA, 2021-2028 (USD MILLION)
    • TABLE 39 NORTH AMERICA: SMART PILLS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.2.1 US
      • 9.2.1.1 Favorable reimbursements for endoscopy procedures to drive market
    • TABLE 40 US: SMART PILLS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 41 US: SMART PILLS MARKET, BY TARGET AREA, 2021-2028 (USD MILLION)
    • TABLE 42 US: SMART PILLS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.2.2 CANADA
      • 9.2.2.1 Rising incidence of IBD to drive market
    • TABLE 43 CANADA: SMART PILLS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 44 CANADA: SMART PILLS MARKET, BY TARGET AREA, 2021-2028 (USD MILLION)
    • TABLE 45 CANADA: SMART PILLS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.2.3 NORTH AMERICA: RECESSION IMPACT
  • 9.3 EUROPE
    • TABLE 46 EUROPE: SMART PILLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 47 EUROPE: SMART PILLS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 48 EUROPE: SMART PILLS MARKET, BY TARGET AREA, 2021-2028 (USD MILLION)
    • TABLE 49 EUROPE: SMART PILLS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.1 GERMANY
      • 9.3.1.1 Rising incidence of Chron's disease to drive market
    • TABLE 50 GERMANY: SMART PILLS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 51 GERMANY: SMART PILLS MARKET, BY TARGET AREA, 2021-2028 (USD MILLION)
    • TABLE 52 GERMANY: SMART PILLS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.2 UK
      • 9.3.2.1 Utilization of capsule endoscopy for bowel cancer to drive market
    • TABLE 53 UK: SMART PILLS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 54 UK: SMART PILLS MARKET, BY TARGET AREA, 2021-2028 (USD MILLION)
    • TABLE 55 UK: SMART PILLS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.3 FRANCE
      • 9.3.3.1 Reimbursement coverage for small bowel capsule endoscopy to drive market
    • TABLE 56 FRANCE: SMART PILLS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 57 FRANCE: SMART PILLS MARKET, BY TARGET AREA, 2021-2028 (USD MILLION)
    • TABLE 58 FRANCE: SMART PILLS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.4 ITALY
      • 9.3.4.1 Rising adoption of technologically advanced endoscopes to support market growth
    • TABLE 59 ITALY: SMART PILLS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 60 ITALY: SMART PILLS MARKET, BY TARGET AREA, 2021-2028 (USD MILLION)
    • TABLE 61 ITALY: SMART PILLS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.5 REST OF EUROPE
    • TABLE 62 REST OF EUROPE: SMART PILLS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 63 REST OF EUROPE: SMART PILLS MARKET, BY TARGET AREA, 2021-2028 (USD MILLION)
    • TABLE 64 REST OF EUROPE: SMART PILLS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.6 EUROPE: RECESSION IMPACT
  • 9.4 ASIA PACIFIC
    • FIGURE 28 ASIA PACIFIC: SMART PILLS MARKET SNAPSHOT
    • TABLE 65 ASIA PACIFIC: SMART PILLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 66 ASIA PACIFIC: SMART PILLS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 67 ASIA PACIFIC: SMART PILLS MARKET, BY TARGET AREA, 2021-2028 (USD MILLION)
    • TABLE 68 ASIA PACIFIC: SMART PILLS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.4.1 JAPAN
      • 9.4.1.1 Rising incidence of gastric cancer to drive market
    • TABLE 69 JAPAN: SMART PILLS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 70 JAPAN: SMART PILLS MARKET, BY TARGET AREA, 2021-2028 (USD MILLION)
    • TABLE 71 JAPAN: SMART PILLS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.4.2 CHINA
      • 9.4.2.1 Increasing funding initiatives for development of smart pills to fuel market
    • TABLE 72 CHINA: SMART PILLS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 73 CHINA: SMART PILLS MARKET, BY TARGET AREA, 2021-2028 (USD MILLION)
    • TABLE 74 CHINA: SMART PILLS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.4.3 INDIA
      • 9.4.3.1 Rising incidence of IBD to support market growth
    • TABLE 75 INDIA: SMART PILLS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 76 INDIA: SMART PILLS MARKET, BY TARGET AREA, 2021-2028 (USD MILLION)
    • TABLE 77 INDIA: SMART PILLS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.4.4 REST OF ASIA PACIFIC
    • TABLE 78 REST OF ASIA PACIFIC: SMART PILLS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 79 REST OF ASIA PACIFIC: SMART PILLS MARKET, BY TARGET AREA, 2021-2028 (USD MILLION)
    • TABLE 80 REST OF ASIA PACIFIC: SMART PILLS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.4.5 ASIA PACIFIC: RECESSION IMPACT
  • 9.5 REST OF THE WORLD
    • TABLE 81 REST OF THE WORLD: SMART PILLS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 82 REST OF THE WORLD: SMART PILLS MARKET, BY TARGET AREA, 2021-2028 (USD MILLION)
    • TABLE 83 REST OF THE WORLD: SMART PILLS MARKET, BY END USER, 2021-2028 (USD MILLION)

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 STRATEGIES ADOPTED BY KEY PLAYERS
    • TABLE 84 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
    • 10.2.1 REVENUE SHARE ANALYSIS
    • FIGURE 29 REVENUE SHARE ANALYSIS OF LEADING PLAYERS
    • 10.2.2 MARKET SHARE ANALYSIS
    • FIGURE 30 SMART PILLS MARKET SHARE, BY KEY PLAYER (2022)
  • 10.3 COMPANY EVALUATION QUADRANT FOR KEY PLAYERS
    • 10.3.1 STARS
    • 10.3.2 EMERGING LEADERS
    • 10.3.3 PERVASIVE PLAYERS
    • 10.3.4 PARTICIPANTS
    • FIGURE 31 SMART PILLS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022)
  • 10.4 COMPANY FOOTPRINT ANALYSIS
    • TABLE 85 SMART PILLS MARKET: COMPANY FOOTPRINT ANALYSIS
    • 10.4.1 APPLICATION FOOTPRINT ANALYSIS
    • TABLE 86 SMART PILLS MARKET: APPLICATION FOOTPRINT
    • 10.4.2 TARGET AREA FOOTPRINT ANALYSIS
    • TABLE 87 SMART PILLS MARKET: TARGET AREA FOOTPRINT
    • 10.4.3 END USER FOOTPRINT ANALYSIS
    • TABLE 88 SMART PILLS MARKET: END USER FOOTPRINT
    • 10.4.4 REGIONAL FOOTPRINT ANALYSIS
    • TABLE 89 SMART PILLS MARKET: REGIONAL FOOTPRINT
  • 10.5 COMPETITIVE SCENARIO
    • 10.5.1 PRODUCT LAUNCHES & APPROVALS
    • TABLE 90 SMART PILLS MARKET: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020-JUNE 2023)
    • 10.5.2 DEALS
    • TABLE 91 SMART PILLS MARKET: DEALS (JANUARY 2020-JUNE 2023)
    • 10.5.3 OTHER DEVELOPMENTS
    • TABLE 92 SMART PILLS MARKET: OTHER DEVELOPMENTS (JANUARY 2020-JUNE 2023)

11 COMPANY PROFILES

  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
  • 11.1 KEY PLAYERS
    • 11.1.1 OLYMPUS CORPORATION
    • TABLE 93 OLYMPUS CORPORATION: BUSINESS OVERVIEW
    • FIGURE 32 OLYMPUS CORPORATION: COMPANY SNAPSHOT (2022)
    • 11.1.2 CAPSOVISION, INC.
    • TABLE 94 CAPSOVISION, INC.: BUSINESS OVERVIEW
    • 11.1.3 MEDTRONIC PLC
    • TABLE 95 MEDTRONIC PLC: BUSINESS OVERVIEW
    • FIGURE 33 MEDTRONIC PLC: COMPANY SNAPSHOT (2022)
    • 11.1.4 INTROMEDIC
    • TABLE 96 INTROMEDIC: BUSINESS OVERVIEW
    • 11.1.5 ANX ROBOTICA CORP.
    • TABLE 97 ANX ROBOTICA CORP.: BUSINESS OVERVIEW
    • 11.1.6 SHENZHEN JIFU MEDICAL TECHNOLOGY CO., LTD.
    • TABLE 98 SHENZHEN JIFU MEDICAL TECHNOLOGY CO., LTD.: BUSINESS OVERVIEW
    • 11.1.7 CHONGQING JINSHAN SCIENCE & TECHNOLOGY (GROUP) CO., LTD.
    • TABLE 99 CHONGQING JINSHAN SCIENCE & TECHNOLOGY (GROUP) CO., LTD.: BUSINESS OVERVIEW
    • 11.1.8 RF CO., LTD.
    • TABLE 100 RF CO., LTD.: BUSINESS OVERVIEW
    • 11.1.9 ETECTRX
    • TABLE 101 ETECTRX: BUSINESS OVERVIEW
    • 11.1.10 BODYCAP
    • TABLE 102 BODYCAP: BUSINESS OVERVIEW
    • 11.1.11 OTSUKA AMERICA PHARMACEUTICAL, INC.
    • TABLE 103 OTSUKA AMERICA PHARMACEUTICAL, INC.: BUSINESS OVERVIEW
    • 11.1.12 CHECK-CAP LTD.
    • TABLE 104 CHECK-CAP LTD.: BUSINESS OVERVIEW
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

12 APPENDIX

  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3 CUSTOMIZATION OPTIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS